Generative AI

Drone Nerds' new partnership with Creality is more than a product expansion. It's a strategic move by parent XTI Aerospace into digital fabrication.

For 14 straight years, Hamilton Lane has been a 'Best Place to Work.' We analyze why this cultural consistency is its most potent strategic asset.

With advanced ZK tech and a key exchange partnership, Mantle is positioning itself as the institutional-grade bridge between Wall Street and tokenized assets.

A record-breaking tech award reveals a new map of global opportunity, data-driven trends, and a masterclass in strategic brand building from inDrive.

A new 31-strain vaccine enters final trials, threatening to upend the market and offer unprecedented protection against a persistent bacterial threat.

A new Solana meme coin is turning failure into a feature, offering tokens to traders for their verified losses. Is it a gimmick or the future of engagement?

The future of boating isn't just in showrooms. It's in garages where DIYers are driving a quiet, clean-energy revolution on the water. Here's how.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

Monaghan Medical just won its 10th Zenith Award, voted on by clinicians. We unpack the strategy behind their decade of dominance in respiratory tech.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

The new SANY-Pony.ai autonomous truck is production-ready for 2026, promising to slash freight costs, boost profits, and redefine logistics.

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.

A breakthrough drug for a rare brain cancer sweeps prestigious international awards, offering patients a new, targeted therapy to delay aggressive treatments.

After two decades under its visionary founder, Oxford Nanopore taps a commercial scaling expert to lead its next chapter of global growth and market dominance.

With promising clinical data and a streamlined FDA path, a smarter molecule could finally offer a better, more tolerable treatment for idiopathic pulmonary fibrosis.

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

Fresh off its spin-off, the US metals processor is in talks to acquire a German giant, a move that could reshape the global steel industry.

A new report shows Business Development Companies are stable, but look closer: dividend pressures and softening credit quality reveal a widening gap.